Novartis and Truffle Capital part of consortium in $25.8m C round for Switzerland's Symetis.

Symetis, a Switzerland-based medical device company, has raised SFr25m ($25.8m) from European investors including local drugs group Novartis’ corporate venturing unit. 

Novartis Venture Fund participated in the round led by venture capital (VC) firms Endeavour Vision and NBGI Ventures as new investors, and also including France-based investment bank Truffle Capital and VC peers Wellington Partners, Vinci Capital’s Renaissance PME fund, Banexi Ventures and BiomedInvest.

In June last year, Symetis raised SFr23m in its series B round.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?